Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03708003Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Mar 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by Swiss Group for Clinical Cancer Research. Started Mar 2019; status: terminated.
02
Drugs
venetoclaxibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03708003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708003.